Ruppert, A. S., Mandrekar, S. J., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., … Woyach, J. A. (2020). Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Ruppert, Amy S., Sumithra J. Mandrekar, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steve E. Coutre, et al. “Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Ruppert AS, Mandrekar SJ, Booth AM, Ding W, Bartlett NL, Brander DM, et al. Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Ruppert, Amy S., et al. “Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Ruppert AS, Mandrekar SJ, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre SE, Brown JR, Nattam SR, Larson RA, Erba HP, Litzow MR, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Woyach JA. Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202. JOURNAL OF CLINICAL ONCOLOGY. 2020.